COHEN & STEERS INC (CNS) Stock Fundamental Analysis
USA - NYSE:CNS - US19247A1007 - Common Stock
71.055 USD
+0.35 (+0.49%)
Taking everything into account, CNS scores 5 out of 10 in our fundamental rating. CNS was compared to 236 industry peers in the Capital Markets industry. While CNS belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. While showing a medium growth rate, CNS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CNS was profitable.
CNS had a negative operating cash flow in the past year.
Each year in the past 5 years CNS has been profitable.
In the past 5 years CNS always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of CNS (21.59%) is better than 98.73% of its industry peers.
CNS has a Return On Equity of 30.67%. This is amongst the best in the industry. CNS outperforms 95.34% of its industry peers.
Looking at the Return On Invested Capital, with a value of 25.18%, CNS belongs to the top of the industry, outperforming 98.31% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for CNS is significantly above the industry average of 7.57%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.59% | ||
| ROE | 30.67% | ||
| ROIC | 25.18% |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
1.3 Margins
The Profit Margin of CNS (29.82%) is better than 74.58% of its industry peers.
In the last couple of years the Profit Margin of CNS has declined.
CNS has a better Operating Margin (33.62%) than 61.86% of its industry peers.
CNS's Operating Margin has declined in the last couple of years.
CNS has a Gross Margin of 88.71%. This is amongst the best in the industry. CNS outperforms 92.80% of its industry peers.
In the last couple of years the Gross Margin of CNS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.62% | ||
| PM (TTM) | 29.82% | ||
| GM | 88.71% |
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
2. Health
2.1 Basic Checks
The number of shares outstanding for CNS has been increased compared to 1 year ago.
CNS has more shares outstanding than it did 5 years ago.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CNS has an Altman-Z score of 10.99. This indicates that CNS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CNS (10.99) is better than 94.92% of its industry peers.
There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 10.99 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.87 indicates that CNS may have some problems paying its short term obligations.
CNS has a Current ratio of 0.87. This is in the lower half of the industry: CNS underperforms 63.56% of its industry peers.
CNS has a Quick Ratio of 0.87. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
CNS's Quick ratio of 0.87 is on the low side compared to the rest of the industry. CNS is outperformed by 63.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.87 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
CNS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.87%, which is quite good.
The Earnings Per Share has been growing slightly by 2.50% on average over the past years.
The Revenue has grown by 11.26% in the past year. This is quite good.
The Revenue has been growing slightly by 4.72% on average over the past years.
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
Revenue 1Y (TTM)11.26%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
3.2 Future
CNS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.06% yearly.
CNS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.09% yearly.
EPS Next Y4.56%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
EPS Next 5Y13.06%
Revenue Next Year7.44%
Revenue Next 2Y8.98%
Revenue Next 3Y7.58%
Revenue Next 5Y8.09%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 23.14, CNS is valued on the expensive side.
Based on the Price/Earnings ratio, CNS is valued a bit more expensive than 62.29% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.83. CNS is around the same levels.
CNS is valuated rather expensively with a Price/Forward Earnings ratio of 20.51.
60.17% of the companies in the same industry are cheaper than CNS, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.82, CNS is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.14 | ||
| Fwd PE | 20.51 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CNS is valued a bit cheaper than the industry average as 75.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 18.1 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CNS has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)5.07
PEG (5Y)9.27
EPS Next 2Y8.74%
EPS Next 3Y8.1%
5. Dividend
5.1 Amount
CNS has a Yearly Dividend Yield of 3.60%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 8.53, CNS has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.34, CNS pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.6% |
5.2 History
The dividend of CNS decreases each year by -7.12%.
CNS has been paying a dividend for at least 10 years, so it has a reliable track record.
CNS has decreased its dividend in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
76.12% of the earnings are spent on dividend by CNS. This is not a sustainable payout ratio.
DP76.12%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
NYSE:CNS (10/24/2025, 11:19:19 AM)
71.055
+0.35 (+0.49%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners60.28%
Inst Owner Change-0.51%
Ins Owners22.51%
Ins Owner Change-0.31%
Market Cap3.62B
Revenue(TTM)552.79M
Net Income(TTM)162.12M
Analysts48
Price Target79.56 (11.97%)
Short Float %7.24%
Short Ratio7.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.6% |
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP76.12%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-3.28%
Min EPS beat(2)-4.27%
Max EPS beat(2)-2.29%
EPS beat(4)0
Avg EPS beat(4)-2.29%
Min EPS beat(4)-4.27%
Max EPS beat(4)-0.35%
EPS beat(8)2
Avg EPS beat(8)-1.05%
EPS beat(12)5
Avg EPS beat(12)0.61%
EPS beat(16)9
Avg EPS beat(16)2.23%
Revenue beat(2)1
Avg Revenue beat(2)0.36%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)1.91%
Revenue beat(4)2
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)6.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.09%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.65%
EPS NY rev (1m)0.16%
EPS NY rev (3m)0.33%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)-0.46%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)1.15%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.14 | ||
| Fwd PE | 20.51 | ||
| P/S | 6.67 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.86 | ||
| P/tB | 7.13 | ||
| EV/EBITDA | 18.1 |
EPS(TTM)3.07
EY4.32%
EPS(NY)3.46
Fwd EY4.88%
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.28
OCFYN/A
SpS10.66
BVpS10.36
TBVpS9.97
PEG (NY)5.07
PEG (5Y)9.27
Graham Number26.75
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.59% | ||
| ROE | 30.67% | ||
| ROCE | 32.81% | ||
| ROIC | 25.18% | ||
| ROICexc | 30.38% | ||
| ROICexgc | 34.72% | ||
| OM | 33.62% | ||
| PM (TTM) | 29.82% | ||
| GM | 88.71% | ||
| FCFM | N/A |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
ROICexc(3y)52.58%
ROICexc(5y)66.96%
ROICexgc(3y)63.61%
ROICexgc(5y)82.87%
ROCE(3y)36.88%
ROCE(5y)49.77%
ROICexgc growth 3Y-36.94%
ROICexgc growth 5Y-14.2%
ROICexc growth 3Y-34.4%
ROICexc growth 5Y-13.57%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
F-Score5
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 55.86% | ||
| Cap/Sales | 1.16% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.87 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 10.99 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)429.54%
Cap/Depr(5y)277.84%
Cap/Sales(3y)4.88%
Cap/Sales(5y)3.14%
Profit Quality(3y)59.63%
Profit Quality(5y)81.14%
High Growth Momentum
Growth
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
EPS Next Y4.56%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
EPS Next 5Y13.06%
Revenue 1Y (TTM)11.26%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
Revenue Next Year7.44%
Revenue Next 2Y8.98%
Revenue Next 3Y7.58%
Revenue Next 5Y8.09%
EBIT growth 1Y16.09%
EBIT growth 3Y-12.76%
EBIT growth 5Y1.55%
EBIT Next Year17.56%
EBIT Next 3Y18.41%
EBIT Next 5Y14.36%
FCF growth 1Y-196.88%
FCF growth 3Y-29.26%
FCF growth 5Y-9.31%
OCF growth 1Y-177.85%
OCF growth 3Y-26.44%
OCF growth 5Y-7.32%
COHEN & STEERS INC / CNS FAQ
What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?
ChartMill assigns a fundamental rating of 5 / 10 to CNS.
Can you provide the valuation status for COHEN & STEERS INC?
ChartMill assigns a valuation rating of 2 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.
Can you provide the profitability details for COHEN & STEERS INC?
COHEN & STEERS INC (CNS) has a profitability rating of 7 / 10.
What are the PE and PB ratios of COHEN & STEERS INC (CNS) stock?
The Price/Earnings (PE) ratio for COHEN & STEERS INC (CNS) is 23.14 and the Price/Book (PB) ratio is 6.86.
What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?
The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 4.56% in the next year.